Last reviewed · How we verify
LAS41007
LAS41007 is a selective phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels.
LAS41007 is a selective phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels. Used for Atopic dermatitis, Psoriasis.
At a glance
| Generic name | LAS41007 |
|---|---|
| Sponsor | Almirall, S.A. |
| Drug class | Phosphodiesterase 4 (PDE4) inhibitor |
| Target | PDE4 |
| Modality | Small molecule |
| Therapeutic area | Immunology/Dermatology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting PDE4, the drug prevents the breakdown of cyclic adenosine monophosphate (cAMP), leading to elevated intracellular cAMP concentrations. This suppresses the production of pro-inflammatory cytokines and chemokines from immune cells, thereby reducing inflammation. The mechanism is particularly relevant for inflammatory and immune-mediated diseases.
Approved indications
- Atopic dermatitis
- Psoriasis
Common side effects
- Nausea
- Diarrhea
- Headache
- Vomiting
Key clinical trials
- Efficacy and Safety Study of LAS41007 in the Treatment of Actinic Keratosis (PHASE2)
- Double-blind, Randomized, Vehicle- and Comparator-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of LAS41007 in the Treatment of Actinic Keratosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LAS41007 CI brief — competitive landscape report
- LAS41007 updates RSS · CI watch RSS
- Almirall, S.A. portfolio CI